Cash Flow Statement (Annual)

RPRX / Repros Therapeutics, Inc. Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.

All numbers are times 1,000 except per share units.

2009 2010 2011 2012 2013 2014 2015 2016
Net Cash Provided By Used In Operating Activities
  Net Income Loss -27,234 -4,768 -12,491 -18,167 -27,721 -32,535 -29,192 -17,273
  Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
    Depreciation And Amortization 72 87 115 145 257 43 24 5
    Share Based Compensation 1,284 609 2,283 2,785 3,158 3,784 3,742 1,928
    Fair Value Adjustment Of Warrants - - - - - - - -
    Increase Decrease In Prepaid Deferred Expense And Other Assets -1,215 150 -229 307 -216 -3 -103 -18
    Increase Decrease In Accounts Payable And Accrued Liabilities 1,854 -568 100 2,049 -358 -629 -6 -259
  Net Cash Provided By Used In Operating Activities -22,081 -4,952 -9,764 -13,495 -24,448 -29,334 -25,329 -15,581
Net Cash Provided By Used In Investing Activities
  Payments To Acquire Property Plant And Equipment - 7 15 30 63 0 0 0
  Net Cash Provided By Used In Investing Activities -502 -371 -335 -608 -911 0 0 0
Net Cash Provided By Used In Financing Activities
  Proceeds From Issuance Of Common Stock And Warrants - - - - - - - -
  Proceeds From Warrant Exercises - - - - - - - -
  Net Cash Provided By Used In Financing Activities 4,999 6,394 11,707 33,750 76,954 147 102 2,876
Cash And Cash Equivalents Period Increase Decrease -17,584 1,071 1,608 19,647 51,595 -29,187 -25,227 -12,705
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents - - - - - - - -
Noncash Investing And Financing Items
  Settlement Of Warrant Liability Due To Cashless Warrant Exercises - - - - - - - -

Peers - Biological Products, Except Diagnostic Substances (Biotech) (2836)

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...

CUSIP: 76028H209